BioMarin Pharmaceutical Inc. (BMRN)
USD 62.03
(-1.08%)
USD 62.03
(-1.08%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.74 Billion USD | 7.24% |
| 2022 | 1.57 Billion USD | 7.73% |
| 2021 | 1.45 Billion USD | 1.79% |
| 2020 | 1.43 Billion USD | -2.56% |
| 2019 | 1.47 Billion USD | 8.93% |
| 2018 | 1.34 Billion USD | 11.38% |
| 2017 | 1.21 Billion USD | 9.0% |
| 2016 | 1.11 Billion USD | 9.04% |
| 2015 | 1.01 Billion USD | 30.41% |
| 2014 | 781.66 Million USD | 28.41% |
| 2013 | 608.75 Million USD | 17.27% |
| 2012 | 519.1 Million USD | 33.17% |
| 2011 | 389.79 Million USD | 30.35% |
| 2010 | 299.03 Million USD | 23.4% |
| 2009 | 242.32 Million USD | 18.65% |
| 2008 | 204.22 Million USD | 27.24% |
| 2007 | 160.51 Million USD | 60.28% |
| 2006 | 100.14 Million USD | 14.77% |
| 2005 | 87.25 Million USD | -46.34% |
| 2004 | 162.6 Million USD | 84.98% |
| 2003 | 87.9 Million USD | 7.8% |
| 2002 | 81.54 Million USD | 56.81% |
| 2001 | 52 Million USD | 0.12% |
| 2000 | 51.94 Million USD | 28.03% |
| 1999 | 40.56 Million USD | 174.11% |
| 1998 | 14.8 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 443.39 Billion USD | -3.7% |
| 2024 Q1 | 427.49 Million USD | -13.9% |
| 2024 Q2 | 460.44 Million USD | 7.71% |
| 2023 Q4 | 496.51 Million USD | 17.46% |
| 2023 FY | 1.68 Billion USD | 7.24% |
| 2023 Q2 | 394.14 Million USD | 1.0% |
| 2023 Q3 | 422.7 Million USD | 7.25% |
| 2023 Q1 | 390.23 Million USD | -10.24% |
| 2022 Q1 | 373.06 Million USD | -5.78% |
| 2022 Q3 | 391.47 Million USD | 5.37% |
| 2022 Q4 | 434.74 Million USD | 11.05% |
| 2022 FY | 1.57 Billion USD | 7.73% |
| 2022 Q2 | 371.52 Million USD | -0.41% |
| 2021 Q2 | 362.95 Million USD | 6.51% |
| 2021 Q4 | 395.94 Million USD | 10.47% |
| 2021 Q1 | 340.77 Million USD | -8.1% |
| 2021 FY | 1.45 Billion USD | 1.79% |
| 2021 Q3 | 358.42 Million USD | -1.25% |
| 2020 Q2 | 372.46 Million USD | 7.89% |
| 2020 FY | 1.43 Billion USD | -2.56% |
| 2020 Q1 | 345.22 Million USD | -8.6% |
| 2020 Q4 | 370.81 Million USD | 7.82% |
| 2020 Q3 | 343.93 Million USD | -7.66% |
| 2019 Q2 | 366.68 Million USD | 0.32% |
| 2019 Q1 | 365.51 Million USD | 5.54% |
| 2019 Q4 | 377.7 Million USD | 4.88% |
| 2019 FY | 1.47 Billion USD | 8.93% |
| 2019 Q3 | 360.13 Million USD | -1.78% |
| 2018 Q4 | 346.34 Million USD | 5.41% |
| 2018 Q2 | 339.08 Million USD | 1.07% |
| 2018 FY | 1.34 Billion USD | 11.38% |
| 2018 Q3 | 328.55 Million USD | -3.11% |
| 2018 Q1 | 335.48 Million USD | -3.94% |
| 2017 Q3 | 288.39 Million USD | -3.85% |
| 2017 FY | 1.21 Billion USD | 9.0% |
| 2017 Q1 | 273.94 Million USD | -15.85% |
| 2017 Q4 | 349.26 Million USD | 21.11% |
| 2017 Q2 | 299.95 Million USD | 9.49% |
| 2016 FY | 1.11 Billion USD | 9.04% |
| 2016 Q4 | 325.56 Million USD | 12.56% |
| 2016 Q3 | 289.24 Million USD | 30.17% |
| 2016 Q2 | 222.2 Million USD | -19.06% |
| 2016 Q1 | 274.53 Million USD | 10.09% |
| 2015 Q2 | 274.88 Million USD | 16.32% |
| 2015 Q4 | 249.37 Million USD | -1.84% |
| 2015 Q3 | 254.05 Million USD | -7.58% |
| 2015 FY | 1.01 Billion USD | 30.41% |
| 2015 Q1 | 236.31 Million USD | -3.07% |
| 2014 Q4 | 243.79 Million USD | 19.96% |
| 2014 FY | 781.66 Million USD | 28.41% |
| 2014 Q1 | 155.19 Million USD | -11.1% |
| 2014 Q3 | 203.22 Million USD | 13.24% |
| 2014 Q2 | 179.45 Million USD | 15.64% |
| 2013 Q2 | 134.29 Million USD | -4.31% |
| 2013 Q1 | 140.34 Million USD | -7.85% |
| 2013 Q4 | 174.56 Million USD | 9.41% |
| 2013 FY | 608.75 Million USD | 17.27% |
| 2013 Q3 | 159.54 Million USD | 18.8% |
| 2012 Q3 | 112.54 Million USD | -12.99% |
| 2012 Q4 | 152.31 Million USD | 35.33% |
| 2012 FY | 519.1 Million USD | 33.17% |
| 2012 Q1 | 119.08 Million USD | 10.48% |
| 2012 Q2 | 129.35 Million USD | 8.62% |
| 2011 Q2 | 90.6 Million USD | 4.9% |
| 2011 Q3 | 103.45 Million USD | 14.19% |
| 2011 Q4 | 107.79 Million USD | 4.19% |
| 2011 FY | 389.79 Million USD | 30.35% |
| 2011 Q1 | 86.36 Million USD | 2.21% |
| 2010 Q3 | 81.68 Million USD | 9.64% |
| 2010 Q2 | 74.5 Million USD | 15.07% |
| 2010 Q1 | 64.75 Million USD | 1.22% |
| 2010 FY | 299.03 Million USD | 23.4% |
| 2010 Q4 | 84.49 Million USD | 3.44% |
| 2009 FY | 242.32 Million USD | 18.65% |
| 2009 Q1 | 64.01 Million USD | 15.24% |
| 2009 Q4 | 63.97 Million USD | 14.84% |
| 2009 Q3 | 55.7 Million USD | -4.98% |
| 2009 Q2 | 58.62 Million USD | -8.42% |
| 2008 Q3 | 56.23 Million USD | 12.35% |
| 2008 Q2 | 50.05 Million USD | 18.07% |
| 2008 Q4 | 55.55 Million USD | -1.2% |
| 2008 Q1 | 42.39 Million USD | -13.49% |
| 2008 FY | 204.22 Million USD | 27.24% |
| 2007 Q2 | 37.92 Million USD | 6.73% |
| 2007 FY | 160.51 Million USD | 60.28% |
| 2007 Q1 | 35.53 Million USD | 18.59% |
| 2007 Q4 | 49 Million USD | 28.79% |
| 2007 Q3 | 38.04 Million USD | 0.31% |
| 2006 Q1 | 19.74 Million USD | -5.84% |
| 2006 FY | 100.14 Million USD | 14.77% |
| 2006 Q4 | 29.96 Million USD | 13.37% |
| 2006 Q3 | 26.43 Million USD | 10.14% |
| 2006 Q2 | 23.99 Million USD | 21.52% |
| 2005 Q4 | 20.97 Million USD | 1.87% |
| 2005 Q2 | 21.92 Million USD | -23.77% |
| 2005 Q1 | 28.75 Million USD | -69.45% |
| 2005 Q3 | 20.58 Million USD | -6.08% |
| 2005 FY | 87.25 Million USD | -46.34% |
| 2004 FY | 162.6 Million USD | 84.98% |
| 2004 Q3 | 26.76 Million USD | 19.77% |
| 2004 Q4 | 94.14 Million USD | 251.72% |
| 2004 Q2 | 22.34 Million USD | 15.59% |
| 2004 Q1 | 19.33 Million USD | -23.01% |
| 2003 Q1 | 24.03 Million USD | -18.2% |
| 2003 FY | 87.9 Million USD | 7.8% |
| 2003 Q4 | 25.11 Million USD | 21.49% |
| 2003 Q3 | 20.67 Million USD | -4.2% |
| 2003 Q2 | 21.57 Million USD | -10.24% |
| 2002 Q3 | 18.61 Million USD | 13.52% |
| 2002 Q4 | 29.38 Million USD | 57.86% |
| 2002 FY | 81.54 Million USD | 56.81% |
| 2002 Q1 | 17.14 Million USD | 35.48% |
| 2002 Q2 | 16.39 Million USD | -4.35% |
| 2001 FY | 52 Million USD | 0.12% |
| 2001 Q4 | 12.65 Million USD | -3.67% |
| 2001 Q3 | 13.13 Million USD | -6.33% |
| 2001 Q2 | 14.02 Million USD | -0.45% |
| 2001 Q1 | 14.08 Million USD | -5.94% |
| 2000 Q3 | 12.76 Million USD | 8.16% |
| 2000 Q4 | 14.97 Million USD | 17.31% |
| 2000 Q2 | 11.8 Million USD | -4.75% |
| 2000 Q1 | 12.39 Million USD | -8.67% |
| 2000 FY | 51.94 Million USD | 28.03% |
| 1999 FY | 40.56 Million USD | 174.11% |
| 1999 Q2 | 8.8 Million USD | -62.39% |
| 1999 Q3 | 11.7 Million USD | 32.95% |
| 1999 Q1 | 23.4 Million USD | 0.0% |
| 1999 Q4 | 13.56 Million USD | 15.97% |
| 1998 FY | 14.8 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Absci Corporation | 73.66 Million USD | -2270.531% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -442.729% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 2.988% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -17472.322% |
| Apollomics, Inc. | 54.14 Million USD | -3125.48% |
| 180 Life Sciences Corp. | 13.47 Million USD | -12856.965% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -5465.462% |
| Bicycle Therapeutics plc | 216.92 Million USD | -705.024% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -1961.328% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -915.855% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -3615.004% |
| Chimerix, Inc. | 93.38 Million USD | -1769.894% |
| CRISPR Therapeutics AG | 463.49 Million USD | -276.763% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -5077.523% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -1399.553% |
| Fortress Biotech, Inc. | 200.19 Million USD | -772.287% |
| Fortress Biotech, Inc. | 200.19 Million USD | -772.287% |
| Gritstone bio, Inc. | 148.37 Million USD | -1076.941% |
| Allakos Inc. | 196.05 Million USD | -790.702% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -3086.866% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -1125.774% |
| Cytokinetics, Incorporated | 173.61 Million USD | -905.849% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -6646.282% |
| Innoviva, Inc. | 132.15 Million USD | -1221.394% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -22601.769% |
| NLS Pharmaceutics AG | 11.8 Million USD | -14690.088% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -1274.349% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -13543214.72% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -1602.719% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -1865.065% |
| ImmuCell Corporation | 9.61 Million USD | -18057.526% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -1006.54% |
| Incyte Corporation | 1.19 Billion USD | -46.685% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -1217.395% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -25852.52% |
| Mustang Bio, Inc. | 48.5 Million USD | -3500.493% |
| MiMedx Group, Inc. | 229.72 Million USD | -660.152% |
| MEI Pharma, Inc. | 34.78 Million USD | -4920.195% |
| MacroGenics, Inc. | 217.21 Million USD | -703.938% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -19673.848% |
| Mereo BioPharma Group plc | 35.84 Million USD | -4772.147% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -9659.81% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -987.751% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -916.162% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -7463.367% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -10892.541% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -16878.853% |
| NextCure, Inc. | 67.63 Million USD | -2481.834% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -3129.059% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -5798.382% |
| Onconetix, Inc. | 34.9 Million USD | -4902.588% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -13600.573% |
| Opthea Limited | 191.96 Million USD | -809.673% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -2826.399% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -63364.331% |
| PDS Biotechnology Corporation | 43.04 Million USD | -3956.837% |
| Precigen, Inc. | 84.18 Million USD | -1974.429% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -2306.464% |
| Prime Medicine, Inc. | 186.63 Million USD | -835.643% |
| PureTech Health plc | 144.59 Million USD | -1107.684% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -572.526% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 37.972% |
| Replimune Group, Inc. | 234.77 Million USD | -643.814% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -20072.609% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -1240.576% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -8892.834% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -250.12% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -7084.363% |
| Sesen Bio, Inc. | 78.38 Million USD | -2127.932% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -663.633% |
| Solid Biosciences Inc. | 104.31 Million USD | -1574.04% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -659.402% |
| SciSparc Ltd. | 9.01 Million USD | -19279.37% |
| Sutro Biopharma, Inc. | 243 Million USD | -618.605% |
| TG Therapeutics, Inc. | 198.47 Million USD | -779.846% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -1338.364% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -23305.375% |
| Travere Therapeutics, Inc. | 472 Million USD | -269.972% |
| UroGen Pharma Ltd. | 138.88 Million USD | -1157.326% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -2373.688% |
| XOMA Corporation | 46.46 Million USD | -3658.421% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -591.452% |
| AbCellera Biologics Inc. | 275.23 Million USD | -534.474% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -2976.649% |
| Cassava Sciences, Inc. | 105.95 Million USD | -1548.098% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -12454.422% |
| Precision BioSciences, Inc. | 92.46 Million USD | -1788.62% |
| Dyadic International, Inc. | 9.15 Million USD | -18979.351% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -20891.405% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -7747.369% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -5783.279% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -1231.073% |
| IGM Biosciences, Inc. | 265.59 Million USD | -557.505% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -1524.109% |
| Acelyrin, Inc. | 422.06 Million USD | -313.746% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -9634.516% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -1970.936% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -25840.13% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -612.754% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -5575.067% |
| Senti Biosciences, Inc. | 94.7 Million USD | -1743.91% |
| Mesoblast Limited | 5.9 Million USD | -29487.852% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -615.329% |
| ChromaDex Corporation | 56.37 Million USD | -2997.386% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -5139.337% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -768.297% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -21614.691% |
| Seer, Inc. | 110.49 Million USD | -1480.482% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -936.759% |
| Novavax, Inc. | 779.12 Million USD | -124.133% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -11030.01% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -587.391% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -3242.089% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -606.599% |
| Celcuity Inc. | 66.23 Million USD | -2536.67% |
| ContextLogic Inc. | 387 Million USD | -351.234% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -940.521% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -5232.789% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 46.361% |
| Amarin Corporation plc | 272.35 Million USD | -541.171% |
| AnaptysBio, Inc. | 181.56 Million USD | -861.775% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -5947.077% |
| Aptorum Group Limited | 10.56 Thousand USD | -16527204.562% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -1475.108% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -291.773% |
| Ardelyx, Inc. | 169.93 Million USD | -927.601% |
| Celularity Inc. | 215.05 Million USD | -712.002% |
| Omeros Corporation | 94.75 Million USD | -1743.015% |
| Humacyte, Inc. | 23.49 Million USD | -7331.906% |
| Immunocore Holdings plc | 308.04 Million USD | -466.899% |
| IO Biotech, Inc. | 91.44 Million USD | -1809.687% |
| GT Biopharma, Inc. | 13.57 Million USD | -12762.957% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -2238.97% |
| Summit Therapeutics Inc. | 87.68 Million USD | -1891.509% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -5825.803% |
| Pulmatrix, Inc. | 22.03 Million USD | -7823.927% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -216.603% |
| Evogene Ltd. | 27.79 Million USD | -6183.825% |
| CorMedix Inc. | 48.95 Million USD | -3466.899% |
| BioLineRx Ltd. | 50.8 Million USD | -3337.414% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -5023.295% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -5233.766% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | -33.117% |
| scPharmaceuticals Inc. | 65.17 Million USD | -2579.24% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -1438.989% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -373.743% |
| NLS Pharmaceutics AG | 11.8 Million USD | -14690.088% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -7084.363% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -910.167% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -4568.186% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -6692.73% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -1313.381% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -2002.603% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -3187.02% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -20559.287% |
| Daré Bioscience, Inc. | 33.6 Million USD | -5095.793% |
| bluebird bio, Inc. | 240.23 Million USD | -626.912% |
| DBV Technologies S.A. | 92.16 Million USD | -1794.83% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -612.306% |
| Galecto, Inc. | 35.62 Million USD | -4801.549% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -4611.513% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -2712.852% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -694.375% |
| GlycoMimetics, Inc. | 39.28 Million USD | -4345.111% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -490.516% |
| ADMA Biologics, Inc. | 66.58 Million USD | -2522.586% |
| Clene Inc. | 41.07 Million USD | -4151.637% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -396.033% |
| Aptose Biosciences Inc. | 52.35 Million USD | -3235.387% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -12018.18% |
| Soligenix, Inc. | 7.79 Million USD | -22301.78% |
| Century Therapeutics, Inc. | 56.07 Million USD | -3014.4% |
| Kura Oncology, Inc. | 165.8 Million USD | -953.216% |
| Surrozen, Inc. | 18.55 Million USD | -9313.881% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -1425.038% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -70267.809% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -1521.455% |
| Autolus Therapeutics plc | 196.72 Million USD | -787.669% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -1962.765% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -8909.312% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -1060.038% |
| GRI Bio, Inc. | 11.33 Million USD | -15312.842% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -24649.844% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -2054.246% |
| INmune Bio, Inc. | 29.89 Million USD | -5741.166% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -912.017% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -4231.65% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -10828.316% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -21108.253% |
| Jaguar Health, Inc. | 42.01 Million USD | -4056.313% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -10993.41% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -2712.128% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -5237.842% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -533.413% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -479.29% |
| Verastem, Inc. | 92.08 Million USD | -1796.394% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -840.248% |
| Histogen Inc. | 14.27 Million USD | -12135.671% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -10781.478% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | -131.575% |
| Surrozen, Inc. | 18.55 Million USD | -9313.881% |
| Organovo Holdings, Inc. | 14.91 Million USD | -11608.18% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -34206.366% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -22778.435% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -880.304% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -3504.435% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -11264.114% |
| Kronos Bio, Inc. | 128.11 Million USD | -1263.021% |
| Turnstone Biologics Corp. | 78.33 Million USD | -2129.154% |
| Synaptogenix, Inc. | 8.31 Million USD | -20904.398% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -11872.268% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -1221.184% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -590.075% |
| Exelixis, Inc. | 1.58 Billion USD | -10.052% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -652.543% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | -104.194% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -2435.942% |
| ESSA Pharma Inc. | 32.13 Million USD | -5334.335% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -10573.91% |
| Avid Bioservices, Inc. | 25.99 Million USD | -6617.476% |
| Insmed Incorporated | 949.26 Million USD | -83.962% |
| MediWound Ltd. | 18.86 Million USD | -9155.22% |
| OmniAb, Inc. | 83.89 Million USD | -1981.501% |
| Alector, Inc. | 248.8 Million USD | -601.873% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -645.29% |
| Zai Lab Limited | 547.47 Million USD | -218.968% |
| AlloVir, Inc. | 180.93 Million USD | -865.15% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -338.043% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -1476.345% |
| Aura Biosciences, Inc. | 84.99 Million USD | -1954.659% |
| Immunic, Inc. | 99.22 Million USD | -1659.95% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -998.203% |
| Veracyte, Inc. | 357.93 Million USD | -387.878% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 80.631% |
| FibroGen, Inc. | 398.11 Million USD | -338.638% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -12189.057% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -573.133% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -25252.62% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -24406.605% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -6649.411% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -451.671% |
| Fortrea Holdings Inc. | 457.3 Million USD | -281.866% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -3117.28% |
| XBiotech Inc. | 37.51 Million USD | -4555.492% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -2435.942% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -931.608% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -4511.358% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -8356.947% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -1129.243% |
| Agenus Inc. | 78.18 Million USD | -2133.574% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -1662.579% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -1477.256% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | -82.236% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -5953.995% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -305.507% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -7727.912% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -992.877% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -31472.797% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -6759.166% |
| Lantern Pharma Inc. | 17.87 Million USD | -9667.966% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -3961.105% |
| Ainos, Inc. | 12.95 Million USD | -13381.977% |
| Pluri Inc. | 22.48 Million USD | -7668.127% |
| Prothena Corporation plc | 282.4 Million USD | -518.356% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -773.041% |
| Rallybio Corporation | 78.93 Million USD | -2112.379% |
| Kodiak Sciences Inc. | 277.32 Million USD | -529.694% |
| Cue Biopharma, Inc. | 19.54 Million USD | -8836.01% |
| MeiraGTx Holdings plc | 151.07 Million USD | -1055.876% |
| Annexon, Inc. | 143.72 Million USD | -1115.028% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -7522.659% |
| Moderna, Inc. | 6.39 Billion USD | 72.689% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -51412.537% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -1910.332% |
| Blueprint Medicines Corporation | 722.86 Million USD | -141.578% |
| Immix Biopharma, Inc. | 16.14 Million USD | -10718.802% |
| CalciMedica, Inc. | 21.81 Million USD | -7904.194% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -1118.521% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -919.455% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -863.191% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -492.078% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -4950.687% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -2306.962% |
| Nutriband Inc. | 5.73 Million USD | -30354.579% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -3904.024% |
| Vor Biopharma Inc. | 126.03 Million USD | -1285.537% |
| Roivant Sciences Ltd. | 1.18 Billion USD | -46.847% |
| Alkermes plc | 996.24 Million USD | -75.286% |
| ProKidney Corp. | 151.52 Million USD | -1052.489% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -2254.264% |
| Arcellx, Inc. | 200.19 Million USD | -772.27% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -184.304% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -1058.776% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -4486.77% |
| Atai Life Sciences N.V. | 125.78 Million USD | -1288.301% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -2039.013% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -2045.064% |
| MediciNova, Inc. | 10.9 Million USD | -15920.482% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -1255.593% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -23954.952% |
| GeoVax Labs, Inc. | 6.02 Million USD | -28897.423% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -266.587% |
| Biomea Fusion, Inc. | 126.13 Million USD | -1284.449% |
| RenovoRx, Inc. | 11.39 Million USD | -15223.578% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -813.854% |
| Geron Corporation | 70.44 Million USD | -2379.06% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -6231.212% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -1207.19% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -621.119% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -566.395% |
| Royalty Pharma plc | 862.4 Million USD | -102.489% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -739.58% |
| Imunon, Inc. | 20.31 Million USD | -8497.924% |
| BioAtla, Inc. | 129.68 Million USD | -1246.53% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -1956.425% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -4081.893% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -740.315% |
| Structure Therapeutics Inc. | 102.77 Million USD | -1599.124% |
| 89bio, Inc. | 151.2 Million USD | -1054.913% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -1470.801% |
| aTyr Pharma, Inc. | 12.97 Million USD | -13354.619% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -1584.683% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -585.448% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -21131.787% |
| Akari Therapeutics, Plc | 16.8 Million USD | -10290.783% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -76694.109% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -483.418% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -910.172% |
| Liquidia Corporation | 87.98 Million USD | -1884.764% |
| Entera Bio Ltd. | 8.86 Million USD | -19609.65% |
| GH Research PLC | 41.22 Million USD | -4136.269% |
| Vericel Corporation | 142.04 Million USD | -1129.425% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -7646.074% |
| Xencor, Inc. | 306.97 Million USD | -468.862% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -35295.51% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -10828.316% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -8422.619% |
| Vaxcyte, Inc. | 468.04 Million USD | -273.103% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -3652.041% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -810.486% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -25852.52% |
| Portage Biotech Inc. | 18.19 Million USD | -9495.445% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -23954.952% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -1563.737% |
| OncoCyte Corporation | 25.63 Million USD | -6711.542% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -28548.09% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -15141.911% |
| Purple Biotech Ltd. | -22.46 Million USD | 7872.622% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -5889.214% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -5558.884% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -591.641% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -10496.329% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -5793.406% |
| United Therapeutics Corporation | 885.1 Million USD | -97.297% |
| HilleVax, Inc. | 133.34 Million USD | -1209.592% |
| Silo Pharma, Inc. | 3.92 Million USD | -44426.75% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -44198.674% |
| Pharming Group N.V. | 225.49 Million USD | -674.432% |
| Tharimmune, Inc. | 9.45 Million USD | -18368.899% |
| Genprex, Inc. | 31.06 Million USD | -5522.161% |
| Apogee Therapeutics, Inc. | 93 Million USD | -1777.654% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -831.218% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -2024.526% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -228171.242% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -31959.867% |
| OKYO Pharma Limited | 8243.57 USD | -21183379.973% |
| Savara Inc. | 15.74 Million USD | -10990.981% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -9903.294% |
| Curis, Inc. | 58.35 Million USD | -2892.503% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -34191.195% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -6362.42% |
| BeiGene, Ltd. | 3.28 Billion USD | 46.867% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -1036.513% |
| Erasca, Inc. | 141.52 Million USD | -1133.899% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -38474.885% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -38474.885% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -3998.371% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -12055.61% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -2518.064% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -3922.378% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -739.031% |
| Adicet Bio, Inc. | 152.03 Million USD | -1048.578% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -308.341% |
| Aditxt, Inc. | 25.95 Million USD | -6629.185% |
| Adagene Inc. | 41.83 Million USD | -4074.56% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -23788.531% |
| Quantum-Si incorporated | 111.65 Million USD | -1463.936% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -11879.029% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -4774.867% |
| Compugen Ltd. | 43.97 Million USD | -3871.424% |
| Generation Bio Co. | 144.46 Million USD | -1108.771% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -2003.186% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -1919.749% |
| Invivyd, Inc. | 205.75 Million USD | -748.716% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -2320.038% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -18519.974% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -2220.508% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -16875.552% |
| 2seventy bio, Inc. | 289.88 Million USD | -502.399% |
| Instil Bio, Inc. | 85.78 Million USD | -1935.641% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -13534.373% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -153813.783% |
| GeoVax Labs, Inc. | 6.02 Million USD | -28897.423% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -4654.095% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -1583.936% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -925.544% |
| Vir Biotechnology, Inc. | 767.72 Million USD | -127.462% |
| Evaxion Biotech A/S | 22.27 Million USD | -7741.379% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -1188.345% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -643.469% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -2084.345% |
| Cingulate Inc. | 22.75 Million USD | -7572.835% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 23408.529% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -3809.542% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -2713.215% |
| Clearmind Medicine Inc. | 8.74 Million USD | -19877.177% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -1977.118% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -59439.173% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1631.952% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -358.947% |
| ImmunityBio, Inc. | 362.87 Million USD | -381.237% |
| Korro Bio, Inc. | 84.53 Million USD | -1965.766% |
| Kineta, Inc. | 21.15 Million USD | -8154.278% |
| BioVie Inc. | 31.95 Million USD | -5365.614% |
| Codexis, Inc. | 66.51 Million USD | -2525.267% |
| Celularity Inc. | 215.05 Million USD | -712.002% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -10629.141% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -670.571% |
| Virax Biolabs Group Limited | 6.54 Million USD | -26572.647% |
| Cibus, Inc. | 320.3 Million USD | -445.191% |
| IN8bio, Inc. | 30.33 Million USD | -5656.255% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -1268.651% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -272755.469% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -124.0% |
| Eyenovia, Inc. | 25.4 Million USD | -6773.354% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -1144.539% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -31296.53% |
| Elevation Oncology, Inc. | 45.44 Million USD | -3742.612% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -2106.76% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -3704.521% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -706.925% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -17438.164% |
| Moolec Science SA | 52.75 Million USD | -3210.436% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -2756.284% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -3652.202% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -1756.318% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -3502.573% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -18621.056% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -7617.137% |
| Humacyte, Inc. | 23.49 Million USD | -7331.906% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -2079.248% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -11910.144% |
| Genelux Corporation | 24.33 Million USD | -7075.981% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -5047.761% |
| Notable Labs, Ltd. | 14.77 Million USD | -11723.121% |
| Immunovant, Inc. | 282.7 Million USD | -517.693% |
| Quantum-Si incorporated | 111.65 Million USD | -1463.936% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -8111.196% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -1611.833% |
| Acasti Pharma Inc. | 11.3 Million USD | -15352.394% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -7518.634% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -4119.686% |
| PepGen Inc. | 84.76 Million USD | -1960.113% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -7526.654% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -5236.124% |
| Immuneering Corporation | 58.41 Million USD | -2889.537% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -34206.366% |
| Belite Bio, Inc | 31.66 Million USD | -5414.32% |
| XOMA Corporation | 46.46 Million USD | -3658.421% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -2485.159% |
| Bionomics Limited | 17.89 Billion USD | 90.24% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 4994.268% |
| uniQure N.V. | 285.08 Million USD | -512.543% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -23788.531% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -799.182% |
| Forte Biosciences, Inc. | 32.47 Million USD | -5276.959% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -20917.288% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -5840.721% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -31296.53% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -12189.057% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -19545.348% |
| Altimmune, Inc. | 30.55 Million USD | -5614.999% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -2369.874% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 4994.268% |
| Peak Bio, Inc. | 1249.13 USD | -139799200.313% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -2256.011% |
| Benitec Biopharma Inc. | 22.38 Million USD | -7702.14% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -618.073% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -6018.05% |
| Zura Bio Limited | 62.63 Million USD | -2687.884% |
| PolyPid Ltd. | 21.04 Million USD | -8197.814% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -6018.05% |
| argenx SE | 1.53 Billion USD | -13.873% |
| Immunome, Inc. | 122.82 Million USD | -1321.816% |
| Verona Pharma plc | 67.15 Million USD | -2500.509% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -6646.282% |
| Shattuck Labs, Inc. | 93.61 Million USD | -1765.399% |
| CervoMed Inc. | 14.95 Million USD | -11574.704% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -20338.612% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -3324.069% |
| Moolec Science SA | 52.75 Million USD | -3210.436% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -10516.66% |
| Design Therapeutics, Inc. | 78.19 Million USD | -2133.374% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -1906.267% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -13775.844% |
| Achilles Therapeutics plc | 75.25 Million USD | -2220.477% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -59439.173% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -3037.791% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -3332.212% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -2541.908% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -3126.488% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -3745.658% |
| Beam Therapeutics Inc. | 554.19 Million USD | -215.102% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -602.757% |
| AEON Biopharma, Inc. | 48.42 Million USD | -3505.846% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -1768.113% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -1990.621% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -13773.754% |
| NeurAxis, Inc. | 8.82 Million USD | -19696.345% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -287.207% |
| Lumos Pharma, Inc. | 38.66 Million USD | -4416.423% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -6489.11% |
| Palisade Bio, Inc. | 13.32 Million USD | -13010.173% |
| Nutriband Inc. | 5.73 Million USD | -30354.579% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -1886.887% |
| Neurogene Inc. | 55.58 Million USD | -3041.743% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -20563.531% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -1705.682% |
| Athira Pharma, Inc. | 125.46 Million USD | -1291.831% |
| HCW Biologics Inc. | 21.02 Million USD | -8204.712% |
| XOMA Corporation | 46.46 Million USD | -3658.421% |
| Nektar Therapeutics | 190.9 Million USD | -814.745% |
| Arvinas, Inc. | 480 Million USD | -263.807% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -76694.109% |
| Merus N.V. | 200.49 Million USD | -770.986% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -1589.589% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -4944.122% |
| Rezolute, Inc. | 70.38 Million USD | -2380.962% |
| Clene Inc. | 41.07 Million USD | -4151.637% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -10562.013% |
| BeyondSpring Inc. | 24.86 Million USD | -6923.024% |
| Synlogic, Inc. | 58.53 Million USD | -2883.453% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -9660.088% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -38775.223% |
| Peak Bio, Inc. | 1249.13 USD | -139799200.313% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -2788.984% |
| Krystal Biotech, Inc. | 160.42 Million USD | -988.524% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -545.261% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -401.748% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -80868.492% |
| MannKind Corporation | 125.59 Million USD | -1290.38% |
| Ikena Oncology, Inc. | 84.57 Million USD | -1964.716% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -18001.741% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -1848.946% |
| Gossamer Bio, Inc. | 183.75 Million USD | -850.307% |
| CohBar, Inc. | 12.38 Million USD | -13996.167% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -3342.7% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -6231.212% |
| Legend Biotech Corporation | 583.14 Million USD | -199.458% |
| Mural Oncology plc | 192.07 Million USD | -809.182% |
| Disc Medicine, Inc. | 91.12 Million USD | -1816.351% |
| Champions Oncology, Inc. | 28.11 Million USD | -6112.291% |
| REGENXBIO Inc. | 321.15 Million USD | -443.745% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -32472.259% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -3031.995% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -4382.151% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -1427.038% |
| Vaxart, Inc. | 90.72 Million USD | -1824.779% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -20396.166% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -3980.646% |
| Cellectis S.A. | 97.32 Million USD | -1694.364% |
| Longeveron Inc. | 21.25 Million USD | -8117.765% |
| Repare Therapeutics Inc. | 167.35 Million USD | -943.443% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -28.325% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -2208.513% |
| Revolution Medicines, Inc. | 498.76 Million USD | -250.12% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -26151.879% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -3872.96% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -2241.165% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -2407.755% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -15689.105% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 63.429% |
| Denali Therapeutics Inc. | 527.23 Million USD | -231.217% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -20072.609% |
| Veru Inc. | 101.34 Million USD | -1623.046% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -7360.482% |
| Cingulate Inc. | 22.75 Million USD | -7572.835% |
| Passage Bio, Inc. | 108.38 Million USD | -1511.118% |
| Context Therapeutics Inc. | 25.07 Million USD | -6864.87% |
| Exicure, Inc. | 14.07 Million USD | -12306.046% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -747.443% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -3932.875% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -18928.221% |
| Nuvalent, Inc. | 149.49 Million USD | -1068.139% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -21547.406% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -1584.781% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -8041.522% |
| OmniAb, Inc. | 83.89 Million USD | -1981.501% |
| Anew Medical, Inc. | 1.3 Million USD | -134142.002% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -5229.859% |
| Lipocine Inc. | 15.08 Million USD | -11479.966% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -2448.823% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -2193.144% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -4231.65% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -1420.576% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -7701.443% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -162.936% |
| Ocugen, Inc. | 71.56 Million USD | -2340.056% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -1760.391% |
| Q32 Bio Inc. | 92.68 Million USD | -1784.198% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -8147.261% |
| Alumis Inc. Common Stock | 158.17 Million USD | -1004.022% |
| Equillium, Inc. | 50.6 Million USD | -3350.727% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -2698.249% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -12458.111% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -9156.639% |
| Dominari Holdings Inc. | 23.83 Million USD | -7226.516% |
| Edesa Biotech, Inc. | 9.22 Million USD | -18834.412% |
| vTv Therapeutics Inc. | 11.9 Million USD | -14565.953% |
| Bio-Techne Corporation | 563.03 Million USD | -210.152% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -327.165% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -549.762% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -1220.165% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -12017.653% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -966.779% |
| Nkarta, Inc. | 131.65 Million USD | -1226.453% |
| BioCardia, Inc. | 12.12 Million USD | -14307.021% |
| Iterum Therapeutics plc | 47.46 Million USD | -3578.847% |